PAH and hyperlipidemia: Initial unadjusted analyses (Model 1) indicated a significant increase in the prevalence of hyperlipidemia associated with Q4 and Q5 of urinary PAH metabolite concentrations (OR = 1.28, 95% CI: 1.07–1.54 and OR = 1.47, 95% CI: 1.21–1.80, respectively).